Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Jimenez Solem, Espen ^a,b   Andersen, Jon Trærup ^a,b   Petersen, Morten ^a,b   Broedbaek, Kasper ^a,b   Andersen, Nadia Lyhne ^c   Torp Pedersen, Christian ^d,e   Poulsen, Henrik Enghusen ^a,b,e  

^a University of Copenhagen   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; COHORT ANALYSIS; DENMARK; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PERINATAL DRUG EXPOSURE; POLYPHARMACY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; ENVIRONMENTAL EXPOSURE; PREGNANCY; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; TIME; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MATERNAL EXPOSURE; PREGNANCY; PREVALENCE; PUBLIC HEALTH; TIME FACTORS; YOUNG ADULT;

EID: 84876697139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063034     Document Type: Article

References (68)

1. Grigoriadis S, Robinson GE, (2007) Gender issues in depression. Ann Clin Psychiatry 19: 247-255 787699661 [pii];10.1080/10401230701653294 [doi].
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, et al. (2003) The epidemiology of major depressive disorder- Results from the National Comorbidity Survey Replication (NCS-R). Jama-Journal of the American Medical Association 289: 3095-3105.
3. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR, (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103: 698-709 10.1097/01.AOG.0000116689.75396.5f [doi];103/4/698 [pii].
4. Chatillon O, Even C, (2010) [Antepartum depression: Prevalence, diagnosis and treatment.]. Encephale 36: 443-451 S0013-7006(10)00041-2 [pii];10.1016/j.encep.2010.02.004 [doi].
5. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, et al. (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49: 726-735.
6. Talati A, Wickramaratne PJ, Pilowsky DJ, Alpert JE, Cerda G, et al. (2007) Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. Soc Psychiatry Psychiatr Epidemiol 42: 962-971 10.1007/s00127-007-0262-4 [doi].
7. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, et al. (2006) Offspring of depressed parents: 20 years later. Am J Psychiatry 163: 1001-1008 163/6/1001 [pii];10.1176/appi.ajp.163.6.1001 [doi].
8. Chung TKH, Lau TK, Yip ASK, Chiu HFK, Lee DTS, (2001) Antepartum Depressive Symptomatology Is Associated With Adverse Obstetric and Neonatal Outcomes. Psychosom Med 63: 830-834.
9. Beck CT, Records K, Rice M, (2006) Further development of the Postpartum Depression Predictors Inventory-Revised. J Obstet Gynecol Neonatal Nurs 35: 735-745 JOGN94 [pii];10.1111/j.1552-6909.2006.00094.x [doi].
10. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356: 2684-2692 356/26/2684 [pii];10.1056/NEJMoa066584 [doi].
11. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA, (2007) First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356: 2675-2683 356/26/2675 [pii];10.1056/NEJMoa067407 [doi].
12. Malm H, Artama M, Gissler M, Ritvanen A, (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118: 111-120 10.1097/AOG.0b013e318220edcc [doi].
13. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT, (2010) First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88: 94-100 10.1002/bdra.20641 [doi].
14. Berard A, Ramos E, Rey E, Blais L, St-Andre M, et al. (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80: 18-27 10.1002/bdrb.20099 [doi].
15. Cole JA, Ephross SA, Cosmatos IS, Walker AM, (2007) Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16: 1075-1085 10.1002/pds.1463 [doi].
16. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, et al. (2008) Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66: 695-705 BCP3261 [pii];10.1111/j.1365-2125.2008.03261.x [doi].
17. Kallen BA, Otterblad OP, (2007) Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79: 301-308 10.1002/bdra.20327 [doi].
18. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH, (2009) Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339: b3569.
19. Reis M, Kallen B (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 1-11. S0033291709992194 [pii];10.1017/S0033291709992194 [doi].
20. Wichman CL, Moore KM, Lang TR, Sauver JLS, Heise RH, et al. (2009) Congenital Heart Disease Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy. Mayo Clinic Proceedings 84: 23-27.
21. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, et al. (2006) Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17: 701-704 10.1097/01.ede.0000239581.76793.ae [doi].
22. Wurst KE, Poole C, Ephross SA, Olshan AF, (2010) First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 88: 159-170 10.1002/bdra.20627 [doi].
23. Malm H, Klaukka T, Neuvonen PJ, (2005) Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106: 1289-1296 106/6/1289 [pii];10.1097/01.AOG.0000187302.61812.53 [doi].
24. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, et al. (1998) Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279: 609-610. jbr71201 [pii].
25. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A, (2008) Duration of antidepressant use during pregnancy and risk of major congenital malformations. The British Journal of Psychiatry 192: 344-350.
26. Einarson A, Choi J, Einarson TR, Koren G, (2009) Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54: 242-246.
27. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, et al. (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16: 1086-1094 10.1002/pds.1462 [doi].
28. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, et al. (2008) Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83: 68-76 10.1002/bdrb.20144 [doi].
29. Simon GE, Cunningham ML, Davis RL, (2002) Outcomes of Prenatal Antidepressant Exposure. Am J Psychiatry 159: 2055-2061.
30. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, et al. (2006) Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 194: 961-966 S0002-9378(06)00225-0 [pii];10.1016/j.ajog.2006.02.019 [doi].
31. Ericson A, Kallen B, Wiholm B (1999) Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55: 503-508. 90550503.228 [pii].
32. Kallen B, Otterblad Olausson P, (2006) Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 21: 221-222 doi:10.1016/j.reprotox.2005.11.006.
33. Lennestal RM, Kallen BM, (2007) Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants. [Article]. Journal of Clinical Psychopharmacology 27: 607-613.
34. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, et al. (2012) Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2. bmjopen-2012-001148 [pii];10.1136/bmjopen-2012-001148 [doi].
35. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, et al. (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344: d8012.
36. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Lander AR, et al. (2013) SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality. Am J Psychiatry. 1566972 [pii];10.1176/appi.ajp.2012.11081251 [doi].
37. Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, et al. (2013) Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 309: 48-54 1555130 fda[pii];10.1001/jama.2012.153812 [doi].
38. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53: 441-449. DMB3816 [pii].
39. Knudsen LB, (1998) The Danish Fertility Database. Dan Med Bull 45: 221-225.
40. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH, (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46: 263-268.
41. Gaist D, Sorensen HT, Hallas J, (1997) The Danish prescription registries. Dan Med Bull 44: 445-448.
42. Sorensen HT, Hansen I, Ejlersen E, Sabroe S, Hamburger H, (1996) Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. J Med Syst 20: 57-65.
43. Statistics Denmark (2008) Containing detailed statistical information on the Danish Society. Available: http://www.dst.dk/en. Accessed 2013 March.
44. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg, et al. (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62: 863-870 10.1007/s00228-006-0177-0 [doi].
45. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, et al. (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198: 194-195 S0002-9378(07)00915-5 [pii];10.1016/j.ajog.2007.07.036 [doi].
46. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT, (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65: 600-606 BCP3048 [pii];10.1111/j.1365-2125.2007.03048.x [doi].
47. Cooper WO, Willy ME, Pont SJ, Ray WA, (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196: 544-545 S0002-9378(07)00144-5 [pii];10.1016/j.ajog.2007.01.033 [doi].
48. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH, et al. (2008) Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 28: 714-716 10.1097/JCP.0b013e31818b53fd [doi];00004714-200812000-00027 [pii].
49. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I (2011) Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry. 10.4088/JCP.10m06090blu [doi].
50. FDA (2009) FDA Advising of Risk of Birth Defects with Paxil. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108527.htm. Accessed 2013 March.
51. Schatzberg AF, (2000) New indications for antidepressants. J Clin Psychiatry 61Suppl 11: 9-17.
52. Goodman JH, (2009) Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. Birth 36: 60-69 BIR296 [pii];10.1111/j.1523-536X.2008.00296.x [doi].
53. De las CC, Sanz E, (2004) Do therapeutic indications of antidepressants change from one year to another? Pharmacoepidemiol Drug Saf 13: 309-314 10.1002/pds.891 [doi].
54. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, Prevention Study TNBD (2010) Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population. J Clin Pharmacol 0091270010373928.
55. Munk-Olsen T, Gasse C, Laursen TM (2012) Prevalence of antidepressant use and contacts with psychiatrists and psychologists in pregnant and postpartum women. Acta Psychiatr Scand.
56. Ramos E, Oraichi D, Rey E, Blais L, Berard A, (2007) Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 114: 1055-1064 BJO1387 [pii];10.1111/j.1471-0528.2007.01387.x [doi].
57. Reefhuis J, Rasmussen SA, Friedman JM, (2006) Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 354: 2188-2190 354/20/2188 [pii];10.1056/NEJMc060602 [doi].
58. Danish Society of Obstetrics and Gynaecology (2012) [Behandling med serotoningenoptagshæmmere i graviditeten og under amningen] DANISH. www dsog dk.
59. Cohen LS, Nonacs RM, Bailey JW, Viguera AC, Reminick AM, et al. (2004) Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Womens Ment Health 7: 217-221 10.1007/s00737-004-0059-3 [doi].
60. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, et al. (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295: 499-507 295/5/499 [pii];10.1001/jama.295.5.499 [doi].
61. O'Brien L, Laporte A, Koren G, (2009) Estimating the economic costs of antidepressant discontinuation during pregnancy. Can J Psychiatry 54: 399-408.
62. Einarson A, Selby P, Koren G, (2001) Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 26: 44-48.
63. de Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC, (1999) Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 60: 33-36 10.1002/ (SICI).
64. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg, et al. (2001) Do pregnant women report use of dispensed medications? Epidemiology 12: 497-501.
65. Paganini-Hill A, Ross RK, (1982) Reliability of recall of drug usage and other health-related information. Am J Epidemiol 116: 114-122.
66. Tilley BC, Barnes AB, Bergstralh E, Labarthe D, Noller KL, et al. (1985) A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol 121: 269-281.
67. Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S, (1991) Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 13: 91-96.
68. West SL, Savitz DA, Koch G, Strom BL, Guess HA, et al. (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142: 1103-1112.